 Cidara Therapeutics, Inc. CDTX, a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the companys lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation BMT. Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections. 